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Abstract: Aims To examine the relationship of sex steroid hormones with osteopenia in a nationally
representative sample of men in the USA. Methods Data on bone mineral density (BMD), serum sex
hormones, dairy consumption, smoking status, and body composition were available for 806 adult male
participants of the cross-sectional National Health and Nutrition Examination Survey (NHANES, 1999-
2004). We estimated associations between quartiles of total and estimated free oestradiol (E2) and
testosterone (T) and osteopenia (defined as 1 to 2.5 SD below the mean BMD for healthy 20- to 29-
year-old men) by applying sampling weights and using multivariate-adjusted logistic regression. We then
estimated the association between serum hormone concentrations and osteopenia by percentage of body
fat, frequency of dairy intake, cigarette smoking status, age, and race/ethnicity. Results Men in the
lowest quartile of total E2 concentrations (< 21.52 pg/ml) had greater odds of osteopenia compared with
men in the highest quartile (odds ratio (OR) 2.29, 95% confidence interval (CI) 1.11 to 4.73; p-trend
= 0.030). Total and free T were not associated with osteopenia. Low total E2 concentrations were
associated with greater odds of osteopenia among non-daily dairy consumers (p-trend = 0.046), current
or former smokers (p-trend = 0.032), and younger men (p-trend = 0.031). No differences were observed
by race/ethnicity and obesity. Conclusion In this nationally representative study of the USA, men with
lower total E2 were more likely to have osteopenia, which was particularly evident among younger men,
men with less-than-daily dairy consumption, and current or former smokers.Cite this article:Bone Joint
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Article focus
  We evaluated the association of plasma 
concentrations of sex steroid hormones 
with osteopenia in a nationally represent-
ative sample of adult men in the USA.
Key messages
  Plasma concentrations of total and free 
testosterone were not associated with 
osteopenia in adult men.
  Men with the lowest total oestradiol (E2) 
concentrations (< 21.52 pg/ml) had twice 
the odds of osteopenia compared with 
men with the highest concentrations.
  low total E2 concentrations were associ-
ated with greater odds of osteopenia 
among non-daily dairy consumers, cur-
rent or former smokers, and younger men.
Strengths and limitations
  The relatively large sample size allowed 
for adjusting for many relevant covariates 
and for examining subgroups of the 
population.
  The cross-sectional design is a limitation 
of our study because it allows only a 
momentary observation of the associa-
tions of sex hormones with osteopenia; 
Relationship of sex steroid hormones 
with bone mineral density of the  
lumbar spine in adult men
Aims
To examine the relationship of sex steroid hormones with osteopenia in a nationally repre-
sentative sample of men in the USA.
Methods
Data on bone mineral density (BMD), serum sex hormones, dairy consumption, smoking 
status, and body composition were available for 806 adult male participants of the cross-
sectional National Health and Nutrition Examination Survey (NHANES, 1999-2004). We 
estimated associations between quartiles of total and estimated free oestradiol (E2) and 
testosterone (T) and osteopenia (defined as 1 to 2.5 SD below the mean BMD for healthy 
20- to 29-year-old men) by applying sampling weights and using multivariate-adjusted 
logistic regression. We then estimated the association between serum hormone concentra-
tions and osteopenia by percentage of body fat, frequency of dairy intake, cigarette smok-
ing status, age, and race/ethnicity.
Results
Men in the lowest quartile of total E2 concentrations (< 21.52 pg/ml) had greater odds of 
osteopenia compared with men in the highest quartile (odds ratio (OR) 2.29, 95% confidence 
interval (CI) 1.11 to 4.73; p-trend = 0.030). Total and free T were not associated with osteope-
nia. Low total E2 concentrations were associated with greater odds of osteopenia among non-
daily dairy consumers (p-trend = 0.046), current or former smokers (p-trend = 0.032), and 
younger men (p-trend = 0.031). No differences were observed by race/ethnicity and obesity.
Conclusion
In this nationally representative study of the USA, men with lower total E2 were more likely 
to have osteopenia, which was particularly evident among younger men, men with less-
than-daily dairy consumption, and current or former smokers.
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we cannot know whether current hormone levels are 
those that influenced a man’s current bone mineral 
density (BMD).
  Due to the younger mean age of our study popula-
tion (42.96 years (95% confidence interval 42.85 to 
43.06)), the prevalence of osteoporosis is low (1%), 
however the wide age range of our study provides 
additional information on hormonal association with 
BMD by age.
Introduction
osteoporosis, which is defined as bone mineral density 
(BMD) > 2.5 SD below the mean for healthy 20- to 
29-year-old men, is a metabolic bone disease that causes 
a deterioration of bone architecture and results in reduced 
bone mass and strength, thus elevating fracture risk.1,2 its 
prevalence increases with age and causes high mortality 
and morbidity among older adults. in 2000, a study esti-
mated nine million osteoporotic fractures among both 
sexes worldwide, of which 39% occurred in men.3 in 
Europe, osteoporotic fractures, after lung cancer, are the 
main cause of disability-adjusted life-years (DAlys) lost, 
outranking several other chronic and neoplastic disor-
ders.3 The lifetime osteoporotic fracture risk for men at 
age 45 years has been estimated at 25.4%.4
in ageing men, an increase in sex hormone binding 
globulin (SHBG) is observed, which causes a gradual 
decrease in bioavailable oestradiol (E2). Serum total tes-
tosterone (T) also declines with increasing age, which 
leads to physiological changes such as loss of muscle 
tone and low BMD.5–10 in both sexes, it is mainly oestro-
gen deficiency that causes an imbalance of bone metabo-
lism with an increase of bone resorption, leading to 
osteopenia (BMD 1 to 2.5 SD below the mean BMD) and 
osteoporosis.11
in this cross-sectional study, we analyzed the associa-
tions of serum total and estimated free E2 and T concen-
trations with osteopenia and BMD across a wide span of 
ages in men. Additionally, we examined whether age, 
race/ethnicity, dairy consumption, cigarette smoking, 
and percentage of body fat modify the association 
between sex hormone levels and osteopenia. We used 
existing data from the National Health and Nutrition 
Examination Survey (NHANES), a nationally representa-
tive sample of Americans.12
Methods
We included men who participated in NHANES 1999-
2004. NHANES is a series of cross-sectional studies con-
ducted by the National Center for Health Statistics 
(NCHS). Participants represent the noninstitutionalized 
population of the USA from ages two months and older. 
The application of a stratified multistage probability 
design with oversampling of certain population sub-
groups including Mexican Americans, non-Hispanic 
blacks, and older adults ensured that adequate sample 
sizes for subanalysis are available.
of the 31,126 individuals who were interviewed in 
NHANES 1999-2004, 15,184 were male. Circulating con-
centrations of total T, total E2, SHBG, and 3α-androstanediol 
glucuronide (AAG) for 1,485 males aged 12 years and 
older were measured in surplus serum, which had been 
aliquoted and stored at −70°C since the interview. Due to 
diurnal variation in hormone levels, only blood samples 
obtained in morning examination sessions were ana-
lyzed. of these 1,485 males we excluded those less than 
20 years old (n = 525), missing sampling weights for the 
morning blood sample (n = 70), and those with missing 
information on BMD (n = 6). in addition, men were 
excluded who were previously diagnosed with prostate 
cancer, because a possible treatment with androgen dep-
rivation therapy affects hormone levels (n = 16).13 Men 
who needed special equipment to walk were also 
excluded, as unloading reduces the mechanical stimulus 
on bone formation and remodelling, which has a direct 
effect on BMD (n = 56).14 After exclusions, 814 men were 
eligible for inclusion in our analysis. Protocols (#98-12) 
for NHANES 1999-2004 were approved by the institutional 
Review Board of the NCHS, Centers for Disease Control 
and Prevention (CDC), and all participants provided 
informed consent.
in NHANES, BMD was measured with dual-energy 
X-ray absorptiometry (DXA) of the lumbar spine using 
Hologic Bone Densitometers (Hologic inc., Marlborough, 
Massachussetts, USA). T-scores were calculated and oste-
openia was defined as 1 to 2.5 SD below the mean BMD 
for healthy 20- to 29-year-old men according to current 
National osteoporosis Foundation (NoF) and World 
Health organization (WHo) recommendations.15,16 Mean 
BMD (1.064 g/cm2) and its SD (0.143) were based on 
values for 20- to 29-year-old non-Hispanic white men in a 
previously published analysis of BMD in NHANES 1999-
2006.17 A total of eight participants were classified as hav-
ing osteoporosis (BMD 2.5 SD below the mean). A 
separate statistical analysis with osteoporosis as the out-
come was not possible, therefore these men were 
excluded from the study. Results were similar when men 
with osteoporosis were included along with the men 
with osteopenia (Supplementary Table i).
For NHANES 1999-2004, the participants had blood 
drawn after an overnight fast. As part of an approved 
ancillary study, sex steroid hormone concentrations in 
the selected samples were analyzed in random order at 
Boston Children’s Hospital, Boston, Massachusetts, USA. 
Plasma concentrations of total E2, total T, and SHBG were 
measured using a competitive electrochemilumines-
cence immunoassay on the 2010 Elecsys autoanalyzer 
(Roche Diagnostics, indianapolis, indiana, USA).
All androgens were eliminated via glucuronidation. 
These metabolites, including AAG, can be measured 
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additionally to total T to reveal the true androgenic 
activity.18–20 AAG was measured using enzyme immuno-
assays (direct androstanediol glucuronide EliSA kit; 
AlPCo Diagnostics, Salem, New Hampshire, USA). The 
lowest detection limits of the assays were 5.0 pg/ml for 
E2, 0.02 ng/ml for T, 0.35 nmol/l for SHBG, and 1.05 
nmol/l for AAG. Coefficients of variation (Cvs) for 
embedded quality control samples were: T, 4.8%; AAG, 
9.7%; E2, 21.4%; and SHBG, 5.6%. Free T and free E2 
were estimated from SHBG, albumin, and total T and E2 
concentrations using mass action equations.21,22
information on physical activity, alcohol consump-
tion, cigarette smoking, and dairy consumption was col-
lected during in-person interviews. The height, weight, 
and waist circumference of the participants were meas-
ured by trained personnel. Body fat percentage was esti-
mated with DXA.
Statistical analysis
Statistical analysis was performed using SUDAAN (RTi 
international, Research Triangle Park, North Carolina, 
USA) as implemented in SAS v9.1 software (SAS institute, 
Cary, North Carolina, USA). in each analysis, sampling 
weights were applied to account for the specific proba-
bilities of selection for the individual domains that were 
over-sampled and non-responsive. Total and free E2, 
total and free T, and AAG were categorized into quartiles 
based on their distributions among all men included in 
the analysis. Selected participant characteristics were 
compared between those with and without osteopenia. 
Multivariate-adjusted linear regression models were used 
to compute geometric mean lumbar spine bone density 
by quartiles, and sex steroid hormone and SHBG concen-
trations. Model 1 took into account age (continuous) and 
race/ethnicity (non-Hispanic white, non-Hispanic black, 
Mexican American, other), smoking status (never, cur-
rent, former), alcohol consumption (more than one alco-
holic drink per month, yes or no), moderate or vigorous 
physical activity in the last month (yes or no), percentage 
body fat (continuous), current dairy consumption (once 
a day or more, yes or no), milk consumption as a child 
(once a day or more, yes or no), milk consumption as a 
teenager (once a day or more, yes or no), and milk con-
sumption as an adult (once a day or more, yes or no). in 
model 2, the hormones were mutually adjusted for each 
other. A test for trend using quartiles of hormones and 
SHBG as an ordinal variable was performed to assess any 
statistically significant linear trend.
Multivariate logistic regression was used to estimate 
the odds ratio (oR) of osteopenia and 95% confidence 
interval (Ci) by quartile of hormone concentrations, with 
the highest quartile as the reference group, with the 
adjustments described above.
Subanalyses were stratified by dairy consumption 
(daily or less than daily), cigarette smoking (ever or never 
smoker), percentage of body fat (< 25%/⩾ 25%), age 
Table I. Baseline characteristics of men aged over 20 years with normal bone mineral density of the lumbar spine or osteopenia; National Health and Nutrition 
Examination Survey 1999-2004
Characteristic* Total Normal BMD Osteopenia†
N (unweighted) 806 623 183
Physical attribute
Mean age, yrs (95% Ci) 42.96 (42.85 to 43.06) 42.92 (42.79 to 43.05) 43.06 (42.83 to 43.28)
Mean BMi, kg/m2 (95% Ci) 27.89 (27.32 to 28.46) 28.41 (27.82 to 28.99) 26.16 (25.20 to 27.11)
Mean body fat, % (95% Ci) 27.86 (27.34 to 28.38) 27.85 (27.23 to 28.47) 27.78 (26.77 to 28.79)
Mean waist circumference, cm (95% Ci) 99.36 (97.91 to 100.81) 100.43 (98.85 to 102.02) 95.57 (93.27 to 97.88)
Age category, %
20 to 39 yrs (young adult) 47.2 47.2 47.2
40 to 59 yrs (middle adult) 37.6 37.6 37.5
over 60 yrs (older adult) 15.3 15.3 15.4
Race and ethnicity, %
Non-Hispanic White 71.5 71.8 71.1
Non-Hispanic Black 10.5 12.4 3.8
Mexican American 8.1 6.9 12.9
other Hispanic 4.4 4.9 3.2
other 5.5 4.0 9.2
Cigarette smoking status, %
Never 45.5 45.8 46.2
Former 26.3 27.0 23.6
Current 28.2 27.2 30.1
> one alcoholic drink per month, % 57.8 57.2 56.9
⩽ poverty income ratio, % 15.8 14.6 22.1
Moderate or vigorous physical activity in the last month, % 25.8 25.3 27.7
Dairy once a day or more, % 48.6 50.8 43.9
Milk consumption as a child, % 78.9 80.6 71.9
Milk consumption as a teenager, % 71.1 73.4 63.3
Milk consumption as an adult, % 50.9 52.2 47.4
*Means (95% confidence interval) and proportions are presented taking into account sampling weights and age; n are unweighted.
†Defined as 1 to 2.5 SD below mean bone mineral density.
BMD, bone mineral density; BMi, body mass index; Ci, confidence interval.
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(20 to 39 years, 40 to 59 years, ⩾ 60 years), and race/
ethnicity (non-Hispanic white, non-Hispanic black, 
Mexican American). A cross-product term was included 
in an unstratified model to assess the presence of interac-
tion between quartiles of each hormone and those char-
acteristics. The coefficients for the cross-product terms 
were evaluated by the Wald test. Statistical significance 
was set at p < 0.05.
Results
of the men included in the analysis, 22.7% (unweighted 
n = 183) had osteopenia (Table i).12 Those with osteope-
nia were more likely to be non-Hispanic white or Mexican 
American and less likely to be non-Hispanic black than 
those with normal BMD. They had a lower mean body 
mass index (BMi) (26.16 kg/m2 (95% Ci 25.20 to 27.11) 
vs 28.41 kg/m2 (95% Ci 27.82 to 28.99)), lower mean 
body fat percentage (27.78% (95% Ci 26.77 to 28.79) vs 
27.85% (95% Ci 27.23 to 28.47)), a lower waist circum-
ference (95.57 cm (95% Ci 93.27 to 97.88) vs 100.43 cm 
(95% Ci 98.85 to 102.02)), and less often consumed 
dairy on a daily basis (43.9% vs 50.8%).
Mean BMD did not statistically significantly differ 
across quartiles of total or free E2 or T, AAG, or SHBG 
(Table ii).12
Total E2 was inversely associated with osteopenia, 
even after adjustment for other hormones. Men in the 
lowest quartile of total E2 (< 21.52 pg/ml) had greater 
odds (oR 2.29, 95% Ci 1.11 to 4.73; p = 0.030) of osteo-
penia compared with men in the highest quartile 
(Table iii).12 The confounder that led to the strongest shift 
in the association of total E2 with osteopenia was smok-
ing. We did not detect a statistically significant association 
of free E2, total or free T, SHBG, or AAG with osteopenia.
Since we observed associations between concentra-
tions of total oestradiol with odds of osteopenia, we 
examined whether results differed by subgroup in the 
study population (Table iv).12 Although we did not 
observe any statistically significant interactions, we noted 
that the association between E2 and osteopenia was only 
statistically significant among young men, men who did 
not consume dairy on a daily basis, and among ever 
smokers.
Discussion
Numerous studies conducted on osteoporosis only include 
elderly men. We included men aged 20 to 90 years and, 
consistent with the majority of other studies, we observed 
a statistically significantly inverse association between 
total E2 serum levels and osteopenia after adjusting for 
potential confounding factors.23–26 like several other 
studies,23,24,27 we did not observe a statistically significant 
association between free T and BMD, or SHBG and BMD.28 
Unlike research conducted in the past,29–31 our results 
showed no positive association between total T and BMD.
We previously conducted a study on sex steroid hor-
mone levels and BMD in men aged over 20 years in 
NHANES iii (1988-1991).28 in NHANES iii, BMD measured 
in the proximal femur region was assessed. in the current 
study, we used BMD of the lumbar spine measured with 
DXA, as previous research suggested a higher impact of 
serum sex steroids on the spine than on other regions of 
the skeleton.28,32 other methods33 to selectively assess 
the trabecular bone in the vertebrae and measure volu-
metric bone loss with a higher sensitivity than DXA were 
not available in NHANES 1999-2004. in contrast to our 
current results, NHANES iii also observed a statistically 
significant positive association of free E2 and T with 
Table II. Adjusted mean bone mineral density of the lumbar spine (g/
cm2) by quartile of serum sex steroid hormones in men aged over 20 years; 
National Health and Nutrition Examination Survey 1999-2004
Sex steroid 
hormone
Adjusted mean bone mineral density (95% CI)
Model 1* Model 2†
Total E2 (pg/ml)
1 (< 21.52) 1.048 (1.009 to 1.087) 1.042 (1.003 to 1.081)
2 (21.52 to < 29.42) 1.041 (1.014 to 1.068) 1.039 (1.012 to 1.066)
3 (29.42 to < 39.29) 1.043 (1.016 to 1.070) 1.044 (1.017 to 1.071)
4 (⩾ 39.29) 1.068 (1.048 to 1.088) 1.072 (1.048 to 1.096)
p-trend‡ 0.249 0.124
Free E2 (pg/ml)
1 (< 0.529) 1.037 (0.996 to 1.078) 1.028 (0.987 to 1.069)
2 (0.529 to < 0.741) 1.040 (1.016 to 1.064) 1.038 (1.014 to 1.062)
3 (0.741 to < 1.003) 1.059 (1.030 to 1.088) 1.060 (1.031 to 1.089)
4 (⩾ 1.003) 1.058 (1.034 to 1.082) 1.064 (1.037 to 1.091)
p-trend‡ 0.203 0.103
Total T (ng/ml)
1 (< 3.67) 1.071 (1.034 to 1.108) 1.077 (1.034 to 1.120)
2 (3.67 to < 4.93) 1.045 (1.021 to 1.069) 1.048 (1.024 to 1.072)
3 (4.93 to < 6.26) 1.048 (1.024 to 1.072) 1.047 (1.023 to 1.071)
4 (⩾ 6.26) 1.042 (1.015 to 1.069) 1.033 (1.004 to 1.062)
p-trend‡ 0.300 0.186
Free T (ng/ml)
1 (< 0.068) 1.100 (1.053 to 1.147) 1.110 (1.059 to 1.161)
2 (0.068 to < 0.095) 1.034 (1.005 to 1.063) 1.038 (1.009 to 1.067)
3 (0.095 to < 0.126) 1.036 (1.018 to 1.054) 1.033 (1.013 to 1.053)
4 (⩾ 0.126) 1.054 (1.027 to 1.081) 1.045 (1.014 to 1.076)
p-trend‡ 0.370 0.179
SHBG (nmol/l)
1 (< 24.05) 1.056 (1.023 to 1.089) 1.048 (1.015 to 1.081)
2 (24.05 to < 33.74) 1.050 (1.023 to 1.077) 1.049 (1.022 to 1.076)
3 (33.74 to < 48.49) 1.045 (1.016 to 1.074) 1.050 (1.019 to 1.081)
4 (⩾ 48.49) 1.048 (1.013 to 1.083) 1.056 (1.017 to 1.095)
p-trend‡ 0.717 0.912
AAG (ng/ml)
1 (< 5.15) 1.038 (1.009 to 1.067) N/A
2 (5.15 to < 6.89) 1.046 (1.019 to 1.073) N/A
3 (6.89 to < 9.61) 1.060 (1.031 to 1.089) N/A
4 (⩾ 9.61) 1.051 (1.029 to 1.073) N/A
p-trend‡ 0.477 N/A
*Model 1 was adjusted for race/ethnicity, age, smoking status, alcohol 
consumption, moderate or vigorous physical activity in the last month, 
percentage of body fat, current dairy consumption, milk consumption as a 
child, milk consumption as a teenager, and milk consumption as an adult.
†Model 2 is as model 1 plus other hormones, excluding 3α-androstanediol 
glucuronide.
‡A test for trend using quartiles of hormones and sex hormone binding 
globulin as an ordinal variable was performed to assess any statistically 
significant linear trend.
AAG, 3α-androstanediol glucuronide; Ci, confidence interval; E2, oestradiol; 
N/A, not applicable; SHBG, sex hormone binding globulin; T, testosterone.
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BMD.28 Trabert et al34 evaluated the association between 
body composition among the same study population 
from NHANES 1999-2004, but unlike us they compared 
total BMD. They observed an inverse association with 
SHBG, an inverse association with total and free T among 
the youngest age group, and a positive association with 
free T among the oldest age group.
Previous research showed that results concerning 
BMD and sex hormones differ depending on which 
region of the skeleton was measured. Snyder et al32 com-
pared the effect of T supplement therapy on BMD of the 
lumbar spine and the proximal femur and found a statis-
tically significant effect on the lumbar spine only. Kelly 
et al35,36 found no association between sex hormone con-
centration and BMD in either hip or lumbar spine, but 
they did find a statistically significant positive association 
between a free T index (ratio of T to SHBG) and BMD at 
the distal radius. They used single and dual photon 
absorptiometry to measure BMD, which are less precise 
than DXA.35,36 Another alternative for the assessment of 
bone quality without using DXA are mean cortical bone 
thickness (CBTavg) and distal femoral cortex index 
(DFCi).37 Bilha et al24 analyzed the correlation between 
sex hormones and the lumbar spine, hip, forearm, and 
total body BMD, but only found a statistically significant 
effect on whole-body BMD.
our observation that hormone concentrations are 
only associated with bone health in young men (20 to 39 
years old), in non-Hispanic white men, in men with low 
dairy consumption, or in smokers has, to the best of our 
Table III. odds of osteopenia (lumbar spine) by quartile of serum sex steroid hormone concentration in men aged over 20 years; National Health and Nutrition 
Examination Survey 1999-2004
Sex steroid hormone Odds ratio (95% CI)
 Model 1* Model 2† Model 3‡
Total E2 (pg/ml)
1 (< 21.52) 1.80 (0.88 to 3.66) 2.15 (1.10 to 4.21) 2.29 (1.11 to 4.73)
2 (21.52 to < 29.42) 1.64 (0.88 to 3.02) 1.73 (0.94 to 3.17) 1.81 (0.98 to 3.33)
3 (29.42 to < 39.29) 1.58 (0.78 to 3.21) 1.61 (0.79 to 3.25) 1.61 (0.79 to 3.30)
4 (⩾ 39.29)§ 1.00 1.00 1.00
p-trend 0.106 0.037** 0.030**
Free E2 (pg/ml)
1 (< 0.529) 1.80 (0.87 to 3.69) 1.99 (0.94 to 4.22) 2.05 (0.89 to 4.69)
2 (0.529 to < 0.741) 1.41 (0.73 to 2.75) 1.45 (0.73 to 2.86) 1.39 (0.68 to 2.84)
3 (0.741 to < 1.003) 1.27 (0.69 to 2.35) 1.25 (0.65 to 2.41) 1.21 (0.63 to 2.32)
4 (⩾ 1.003)§ 1.00 1.00 1.00
p-trend¶ 0.127 0.089 0.116
Total T (ng/ml)
1 (< 3.67) 0.73 (0.39 to 1.40) 0.90 (0.37 to 2.20) 0.64 (0.22 to 1.87)
2 (3.67 to < 4.93) 1.17 (0.65 to 2.11) 1.23 (0.62 to 2.42) 0.97 (0.45 to 2.10)
3 (4.93 to < 6.26) 0.98 (0.52 to 1.87) 0.99 (0.51 to 1.91) 0.83 (0.40 to 1.72)
4 (⩾ 6.26)§ 1.00 1.00 1.00
p-trend¶ 0.594 0.941 0.574
Free T (ng/ml)
1 (< 0.068) 0.86 (0.30 to 2.50) 0.98 (0.31 to 3.08) 0.68 (0.18 to 2.56)
2 (0.068 to < 0.095) 1.89 (0.87 to 4.12) 2.09 (0.93 to 4.70) 1.65 (0.70 to 3.90)
3 (0.095 to < 0.126) 1.74 (0.80 to 3.81) 1.79 (0.81 to 3.96) 1.60 (0.71 to 3.62)
4 (⩾ 0.126)§ 1.00 1.00 1.00
p-trend¶ 0.835 0.584 0.819
SHBG (nmol/l)
1 (< 24.05) 0.77 (0.40 to 1.47) 0.93 (0.43 to 2.04) 0.99 (0.43 to 2.28)
2 (24.05 to < 33.74) 1.10 (0.61 to 1.99) 1.18 (0.61 to 2.27) 1.18 (0.56 to 2.46)
3 (33.74 to < 48.49) 0.89 (0.51 to 1.57) 1.01 (0.56 to 1.82) 0.96 (0.51 to 1.81)
4 (⩾ 48.49)§ 1.00 1.00 1.00
p-trend¶ 0.579 0.943 0.922
AAG (ng/ml)
1 (< 5.15) 1.63 (0.93 to 2.87) 1.57 (0.86 to 2.88) N/A
2 (5.15 to < 6.89) 1.10 (0.59 to 2.05) 1.14 (0.61 to 2.13) N/A
3 (6.89 to < 9.61) 1.07 (0.60 to 1.90) 1.10 (0.61 to 1.98) N/A
4 (⩾ 9.61)§ 1.00 1.00 N/A
p-trend¶ 0.133 0.167 N/A
*Adjusted for age and race/ethnicity.
†As with Model 1, plus smoking status, alcohol consumption, moderate or vigorous physical activity in the last month, percentage of body fat, current dairy 
consumption, milk consumption as a child, milk consumption as a teenager, and milk consumption as an adult.
‡As with Model 2 plus other hormones, excluding 3α-androstanediol glucuronide (AAG).
§Reference point.
¶A test for trend using quartiles of hormones and sex hormone binding globulin as an ordinal variable was performed to assess any statistically significant 
linear trend.
**Statistically significant.
AAG, 3α-androstanediol glucuronide; Ci, confidence interval; E2, oestradiol; N/A, not applicable; SHBG, sex hormone binding globulin; T, testosterone.
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knowledge, not been described by other studies. Previous 
observational evidence supports a beneficial effect of 
dairy intake on bone strength and BMD in older men.38,39
To our knowledge, this is one of a few studies that 
examined the association between sex hormones and 
osteopenia in young and middle-aged men. With the 
relatively large sample size and possibility to adjust for 
many relevant covariates, enabled by the thorough 
standardized measurement of demographic information, 
laboratory analyses, and body measurements in NHANES 
1999-2004, it was possible to detect even small differ-
ences between groups. Unlike other studies, we adjusted 
for a variety of confounders.28,40,41
limitations of this study include the cross-sectional 
design. The design allows only a momentary observation 
of the associations of sex hormones with osteopenia, so 
we cannot know whether current hormone levels are 
those that influenced a man’s current BMD. Additionally, 
we did not directly measure free E2 and T and instead esti-
mated them from measured total E2 or T and SHBG. The 
equation that we used to calculate free E2 has only been 
verified in postmenopausal women.22 Due to the younger 
mean age of our study population (42.96 years (95% Ci 
42.85 to 43.06)), the prevalence of osteoporosis is low 
(1%, eight cases), but the wide age range of our study pro-
vides additional information on hormonal association with 
BMD by age. indeed, a statistically significant association 
between low total E2 and odds of osteopenia was seen in 
the youngest but not in the middle and older age groups.
in summary, men with lower total E2 in our study were 
more likely to have low BMD of the lumbar spine. This was 
particularly evident among younger men, men who did 
not consume dairy or consumed dairy less than daily, and 
ever smokers. These results, which focused on the associa-
tion between sex hormones and osteopenia in the lumbar 
spine, should be expanded by studies analyzing the asso-
ciation of hormone levels with other regions of the skele-
ton and their impact on fracture risk in each region.
Supplementary Material
Table showing results from the National Health and 
Nutrition Examination Survey 1999-2004, illustrat-
ing the effect of sex steroid hormones on adjusted bone 
mineral density and odds of osteopenia/osteoporosis in 
men aged over 20 years.
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